You have one industry making billions of dollars making us sick
On December 19, 2025, Eli Lilly announced that retatrutide produced 28.7% body weight loss in the Phase 3 TRIUMPH-4 trial
While Alnylams Phase III APOLLO-B study hit both key primary and secondary endpoints, the FDA stated in the documents that the effects of patisiran compared to placebo on both endpoints were small, of questionable clinical meaningfulness, and may not be detectable by patients. Major discussion points during the adcomm meeting included whether these key endpoints were appropriate to ascertain clinical meaningfulness in the ATTR-CM population, and panelists expressed varying opinions on whether the magnitude of the benefit seen in trial data was clinically meaningful
It is a synthetic peptide with structural modifications that protect it from rapid degradation
Pauly RP, Demuth HU, Rosche F, Schmidt J, White HA, Lynn F, McIntosh CH, Pederson RA
Elgoweini M, Nour El Din N